

Bibliografía

1. Ternant D, Arnoult C, Pugnière M, Dhommée C, Drocourt D, Perouzel E, *et al.* IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding. *J Immunol.* 2016;196:607-13.
2. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, *et al.* Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. *Lancet.* 1999;354:1932-9.
3. Edwards JCW, Szczepański L, Szechiński J, Filipowicz-Sosnowska A, Emery P, Close DR, *et al.* Efficacy of B-Cell-Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis. *N Engl J Med.* 2004;350:2572-81.
4. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, *et al.* Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. *Arthritis Rheum.* 2004;50:1761-9.
5. Food and Drug Administration (FDA). Arthritis Advisory Committee Meeting. FDA Briefing Document. [Internet]. FDA; 2017. Disponible en: <https://www.fda.gov/media/106325/download>
6. EMEA. Kevzara (sarilumab). [Internet]. European Medicines Agency. [Fecha de acceso: 28 Feb 2020]. Disponible en: <https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara>
7. AEMPS. Kevzara 150 mg solución inyectable en jeringa precargada. N^o de registro 1171196001. [Internet]. Agencia Española de Medicamentos y Productos Sanitarios. [Fecha de acceso: 28 Feb 2020]. Disponible en: <https://cima.aemps.es/cima/publico/detalle.html?nregistro=1171196001>
8. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics review(s). Application number: 761037 (related IND 100632).
9. EMEA. Kevzara (sarilumab). Annex I Summary Of Product Characteristics [Internet]. European Medicines Agency. [Fecha de acceso: 28 Feb 2020]. Disponible en: https://www.ema.europa.eu/en/documents/product-information/kevzara-epar-product-information_en.pdf
10. Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K, *et al.* IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. *Science.* 1993;260:1808-10.
11. Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. *Nat Rev Drug Discov.* 2018;17:395-412.
12. Kim GW, Lee NR, Pi RH, Lim YS, Lee YM, Lee JM, *et al.* IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future. *Arch Pharm Res.* 2015;38:575-84.
13. Rafique A, Martin J, Blome M, Huang T, Ouyang A, Papadopoulos N. Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human IL-6 receptor (il-6r) alpha. *Ann Rheum Dis.* 2014;72:A797.
14. Potocky T, Rafique A, Fairgurst J, Lazo M, Martin J, Huang T, *et al.* Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human IL-6 receptor alpha (il-6r α). *Modern Rheumatology.* 2016;26:S69. ICW-C15-3.
15. Maldonado R. Farmacología de sarilumab en la artritis reumatoide. *Reumatol Clin Supl.* 2018;14:16-21.
16. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. *J Pharm Sci.* 2004;93:2645-8.
17. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies. *Clin Pharmacokinet.* 2010;49:493-507.
18. Ferri N, Bellosta S, Baldessin L, Boccia D, Racagni G, Corsini A. Pharmacokinetics interactions of monoclonal antibodies. *Pharmacol Res.* 2016;111:592-9.
19. Belomestnov P, Hamilton J, DiCioccio A, Jasson M, Radin A. Sarilumab, a sub-cutaneously-administered, fully human monoclonal antibody inhibitor of the IL-6 receptor: pharmacokinetic profile and its relationship to changes in pharmacodynamic markers in patients with rheumatoid arthritis. [Abstract 1337]. En: 2012 ACR/ARHP Annual Meeting. ACR; 2012.
20. Radin AR, Mellis S, Jasson M, Nadler D, Belomestnov P, Pavel W, *et al.* REGN88/SAR153191 A fully-human interleukin-6 receptor monoclonal antibody, reduces acute phase reactants in patients with rheumatoid arthritis: preliminary observations from phase 1 studies. [Abstract]. *Arthritis Rheumatol.* 2010;62:S470.
21. Huizinga TWJ, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, *et al.* Sarilumab, a fully human monoclonal antibody against IL-6R α in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. *Ann Rheum Dis.* 2014;73:1626-34.
22. Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, *et al.* Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. *Arthritis Rheumatol.* 2015;67:1424-37.

23. Emery P, Rondon J, Parrino J, Lin Y, Pena-Rossi C, van Hoogstraten H, *et al.* Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2019;58:849-58.
24. Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, *et al.* Sarilumab and non biologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. *Arthritis Rheumatol*. 2017;69:277-90.
25. Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NMH, *et al.* Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. *Ann Rheum Dis*. 2017;76:840-7.
26. Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, *et al.* Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. *Arthritis Res Ther*. 2018;20:129.
27. Kivitz A, Baret-Cormel L, van Hoogstraten H, Wang S, Parrino J, Xu C, *et al.* Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis. *Rheumatol Ther*. 2017;5:231-42.
28. Fleischmann R, Genovese MC, Lin Y, St John G, van der Heijde D, Wang S, *et al.* Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up. *Rheumatology*. 2020;59:292-302.
29. Tanaka Y, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, Graham NM, *et al.* Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. *Arthritis Res Ther*. 2019;21:79.
30. Kameda H, Wada K, Takahashi Y, Hagino O, van Hoogstraten H, Graham N, *et al.* Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA). *Mod Rheumatol*. 2020;30:239-48.
31. US Food and Drug Administration. Center for drug evaluation and research. *Clin Pharmacol Biopharm*. 2015;351:37.
32. Kevzara. Highlights of prescribing information. [Internet]. Regeneron Pharmaceuticals, Inc./Sanofi-Aventis U.S. LLC; 2017. [Actualizado May 2017]. [Fecha de acceso: 28 Feb 2020]. Disponible en: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761037s000lbl.pdf
33. Xu C, Su Y, Paccaly A, Kanamaluru V. Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis. *Clin Pharmacokinet*. 2019;58:1455-67.
34. Lee EB, Daskalakis N, Xu C, Paccaly A, Miller B, Fleischmann R, *et al.* Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis. *Clin Pharmacokinet*. 2017;56:607-15.
35. Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. *Clin Pharmacol Ther*. 2011;89:735-40.
36. Center for Drug Evaluation and Research. Tocilizumab. Application number: 125472Orig1s000. [Internet]. Clinical Pharmacology and Biopharmaceutics Review(s); 2013. [Fecha de acceso: 28 Feb 2020]. Disponible en: www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125472Orig1s000ClinPharmR.pdf
37. Xu C, Nolain P, Lu Q, Paccaly A, Iglesias-Rodríguez M, St John G, *et al.* Sarilumab and tocilizumab receptor occupancy (RO), and effects on C-reactive protein (CRP) levels, in patients with rheumatoid arthritis (RA). [Abstract 1398]. En: 2019 ACR/ARP Annual Meeting. ACR; 2019.
38. Abdallah H, Hsu JC, Lu P, Fettner S, Zhang X, Douglass W, *et al.* Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA. *J Clin Pharmacol*. 2017;57:459-68.
39. Gibiansky L, Frey N. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach. *J Pharmacokinet Pharmacodyn*. 2012;39:5-16.
40. Potocky T, Rafique A, Fairhurst J, Lazo M, Martin J, Huang T, *et al.* Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human IL-6 receptor (IL-6Rr) alpha. *Modern Rheumatol*. 2016; 26:S69. ICW-C15-3.